Illuminating The Path How Tumor-Targeting Dyes Could Revolutionize Cancer Treatment
Description
Cancer is among the most complex and widely studied diseases on Earth, affecting millions of lives and challenging the limits of medical science. How close are we getting to uncovering sustainable detection and treatment methods? Lyle Small, the founder and current CEO of Lahjavida, Inc., joins the Good Question Podcast to share his thoughts…
Lahjavida is a cancer research firm dedicated to the development of new cancer treatments. They are known for their patented invention of a new cancer treatment that uses the tumor-targeting capabilities of NIR fluorescent dyes to work in conjunction with therapeutic agents.
With a background in entrepreneurship and engineering, Lyle brings an important perspective to the table. He served as the Founder and CEO of Chromatic Technologies, Inc. for more than 30 years, a company that pioneered several breakthroughs in the dye industry. now, he leverages his extensive experience and knowledge in this unique field to help in the battle against cancer.
Jump in to explore:
- The role that dyes can play in the identification and treatment of cancer.
- What Dye Drug Conjugates (DDCs) are, and how they intersect with medical applications.
- What the future of cancer treatment may look like.
To follow along with Lyle’s work with Lahjavida and learn more about their innovative cancer treatments, click here!
Episode also available on Apple Podcasts: https://apple.co/38oMlMr
United States
